May 2026 in “Indian Journal of Dermatology” Tofacitinib shows promise for treating alopecia areata with significant hair regrowth and mild side effects.
January 1982 in “Clinical Cosmetic and Investigational Dermatology” Familial dyskeratotic comedones are a rare, inherited skin condition that is hard to treat but may improve slightly with topical retinoids and urea cream.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
5 citations
,
September 2020 in “Proceedings - Baylor University. Medical Center” Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
December 2023 in “Reactions weekly” December 2023 in “Reactions weekly” September 2013 in “Reactions weekly” 3 citations
,
August 2019 in “Journal of Cancer Research and Therapeutics” Cetuximab can cause unusual hair growth and hair loss.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
September 2021 in “Clinical research in dermatology” 5-Alpha-Reductase inhibitors might help slow down hair loss in Frontal Fibrosing Alopecia but are not a primary treatment and need more research.
9 citations
,
January 2018 in “Journal of the European Academy of Dermatology and Venereology” A male patient developed frontal fibrosing alopecia after antiandrogen therapy for prostate cancer.
26 citations
,
October 2017 in “PubMed” Isotretinoin and acitretin may effectively stabilize the hairline in patients with frontal fibrosing alopecia.
1 citations
,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
4 citations
,
March 2008 in “Journal of the American Academy of Dermatology”
98 citations
,
January 2013 in “Journal of The American Academy of Dermatology” Dutasteride may help stabilize Frontal Fibrosing Alopecia, but more research is needed.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
Low-dose sorafenib can cause severe facial acne, treatable with topical medication.
3 citations
,
August 2024 in “Clinical Cosmetic and Investigational Dermatology” The 1927 nm fractional thulium laser effectively treats acne by targeting and improving affected skin areas.
15 citations
,
December 2019 in “European Journal of Dermatology” Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
26 citations
,
October 2019 in “JNCI Cancer Spectrum” Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
4 citations
,
July 1996 in “Annals of Internal Medicine” High doses of fluconazole can cause reversible hair loss.
1 citations
,
January 2022 in “European Journal of Pharmacology” Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
Tofacitinib helped a woman with total-body hair loss grow her hair back.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
9 citations
,
October 1947 in “The Lancet” 1 citations
,
November 1947 in “The Lancet” August 2023 in “Journal of Investigative Dermatology” Dutasteride may help treat frontal fibrosing alopecia.
June 2020 in “Journal of Investigative Dermatology” Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.